Cesium chloride as a cancer treatment

MS-N142 · Cancer control · Unsupported claim · High risk · Human evidence · Appraised 26 October 2026

Can non-radioactive cesium chloride or other cesium salts safely treat cancer by making the body or tumor more alkaline?

Evidence at a glance

Evidence label: No credible cancer-control evidence; documented life-threatening toxicity
Benefit: No clinical evidence shows that cesium salts shrink tumors or improve survival.
Certainty: Moderate to high that the cancer claim is unsupported; case-report evidence consistently identifies serious cardiac and electrolyte toxicity.
Risk: High—hypokalemia, QT prolongation, ventricular arrhythmias, seizures, syncope and death have been reported.

What was studied

Claim and formulation: Non-radioactive cesium chloride has been promoted as “high-pH” cancer therapy, usually by mouth and sometimes by injection. This is distinct from radioactive cesium used in tightly controlled medical or industrial contexts.

Human evidence: No randomized efficacy trial was found. A 2025 review assembled 20 published intoxication cases; cancer was the reason for use in 18. FDA has separately reviewed clinical case reports, adverse-event data and nonclinical evidence.

What the evidence found

The proposed mechanism is not supported: taking cesium does not selectively alkalinize cancer cells, and no clinical evidence demonstrates cancer vulnerability to this approach.

In the 20-case review, many people developed arrhythmia or presyncope; five (25%) were reported to have died because of cesium intake. Individual cases describe severe hypokalemia, QT prolongation, torsades de pointes, seizures, cardiac arrest and death.

FDA’s 5 February 2020 public-health alert states that cesium salts have never been proven safe and effective for cancer or any other use and advises consumers not to use them.

How to interpret it

This is a high-risk unsupported cancer claim, not a reasonable self-experiment. Case reports cannot calculate a population incidence, but repeated, mechanistically coherent, sometimes fatal events are sufficient to establish a serious safety signal.

Lowering urinary pH or changing a laboratory value would not prove that a tumor’s microenvironment changed or that cancer was controlled.

Practical safety context

Do not start or continue cesium salts for cancer treatment. Exposure with fainting, palpitations, seizure, severe weakness or vomiting requires urgent medical assessment and ECG/electrolyte evaluation. Because cesium can persist in the body, risk may not end immediately after stopping.

Questions for the care team

Has this product been promoted with “alkaline,” “high-pH” or selective cancer-cell claims?
Are potassium, magnesium and the QT interval already abnormal or affected by current treatment?
What evidence-based cancer or symptom-management option is being displaced?

Funding and conflicts

The 2025 case-review funding and conflicts were checked only at abstract level; detailed declarations were not verified. FDA’s alert is a regulator safety communication, not an efficacy trial.

Sources

Last literature search: 26 October 2026. Record appraisal: 26 October 2026. This page is educational and does not replace individualized medical advice. Laboratory effects, biomarkers, symptom changes or an uncontrolled response must not be interpreted as proof of tumor control, delayed recurrence or longer survival.